Overview

This trial is active, not recruiting.

Condition amphetamine-related disorders
Treatment aripiprazole
Phase phase 1
Sponsor National Institute on Drug Abuse (NIDA)
Start date June 2004
End date March 2005
Trial size 17 participants
Trial identifier NCT00089440, NIDA-MDS-0002-1

Summary

The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Primary purpose treatment

Primary Outcomes

Measure
Adverse effect measures
time frame:
pharmacokinetic assessment
time frame:

Eligibility Criteria

Male or female participants from 18 years up to 45 years old.

Inclusion Criteria: - Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking. - Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures. Exclusion Criteria: - Please contact the site for more information.

Additional Information

Official title Assessment of Interactions Between IV Methamphetamine and Aripiprazole
Principal investigator Thomas Newton, M.D.
Description This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.
Trial information was received from ClinicalTrials.gov and was last updated in October 2007.
Information provided to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA).